Consultant Urges Malaysian Biotechs, Industries To Talk To Each Other
This article was originally published in PharmAsia News
A Malaysian consultant says biotechnology researchers and the industries that could benefit from their products are losing out on research grants because they are not communicating with each other. Biomillennium Consultancy's executive director said many biotech commercialization efforts have failed because of that lack of communication. Abdul Reezal said the government offers funds for research and development activities in universities, but the industrial sector has been largely inactive in investing in biotech. He urged a change in the mindset of those in industry and even on the part of some in government. (Click here for more
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.